Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 74Colonic Neoplasms 31Rectal Neoplasms 29Neoplasm Metastasis 16Stomach Neoplasms 12Pancreatic Neoplasms 12Esophageal Squamous Cell Carcinoma 8Small Cell Lung Carcinoma 7Neoplasms 6Esophageal Neoplasms 6Rhabdomyosarcoma 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Uterine Cervical Neoplasms 3Sarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Cholangiocarcinoma 3Biliary Tract Neoplasms 3Rectal Diseases 2Neuroblastoma 2Neoplasms by Histologic Type 2Intestinal Diseases 2Hepatoblastoma 2Gastrointestinal Diseases 2Ganglioneuroblastoma 2Digestive System Diseases 2Colorectal Cancer Metastatic 2Colorectal Adenocarcinoma 2Colonic Diseases 2

Interventions

Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Cirrhosis, Familial, with Pulmonary Hypertension × Irinotecan × Clear all
NCT07328919 2026-01-09

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

TransThera Sciences (Nanjing), Inc.

Phase 3 Not yet recruiting
138 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡